Anti-Obesity Drugs | sciencenewsnet.in

Breaking News

Penn Study Highlights Inconsistencies of Genetic Markers for Predicting Heart Disease

New study shows how salmonella tricks gut defenses to cause infection

How ecDNA Fuels Cancer by Breaking the Laws of Biology

Creating a spatial map of the sea

Much Ado About Vacuum

Researchers Uncover Achilles Heel of Antibiotic-Resistant Bacteria

HSS Appoints Daphne A. Scott, MD, Chief of Primary Sports Medicine

Study: Coronary Function Testing Improves Diagnosis of Heart Disease in Women

Multi-disciplinary teams respond to recent hurricanes to measure real time impacts of storm surge, waves

New pathways for Alzheimer’s prevention

17 Nov, 2024

Two medication classes reduced cardiovascular and liver events in people with type 2 diabetes

June 2, 2024 sarah JonasResearch Results

GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

Anti-obesity medication tirzepatide remains effective even for those with diabetes and other complications

June 1, 2024 sarah JonasResearch Results

Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.